USA-based RODES and Ligand Pharmaceuticals (Nasdaq: LGND) have signed exclusive global license and supply agreements for three Captisol-enabled (CE) programs, with the news lifting Ligand’s shares 3.56% to $109.34 in New York trading yesterday.
Under the terms of the agreements, for each program Ligand will be eligible to receive development and commercial milestone payments, revenue from the sales of Captisol, and royalties of 8% to 11% on future net sales. RODES, which specializes in growth investment and turnaround opportunities in the pharmaceuticals and biologics industry, will be responsible for all costs related to the development and commercialization of the programs.
The three programs are:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze